

Index

A

Adrenocorticotrophic hormone (ACTH), 285
Aggression, 198, 199, 201–208, 212, 216, 218
Alpha, 133
Amantadine, 261
Amygdala, 59, 151, 209, 210, 212–215
Anterior cingulate cortex (ACC), 132, 144, 145, 208, 209, 215
Anticipation of punishment, 212
Anticonvulsants, 50
Antipsychotic, 50
 aripiprazole, 259, 260
 risperidone, 259, 260
Antisocial personality disorder (ASPD), 198
Antisocial process screening device, 199
Anxiety disorders (AD), 286
Assessment, 48, 49
Attention-deficit hyperactivity disorder (ADHD), 246, 350–357, 359, 360, 362
 childhood sexual abuse, 38
 corpus callosum, 40
Autism spectrum disorder (ASD), 257, 258
Autonomic nervous system (ANS), 49
Autonomic reactivity, 203, 204
Aversive conditioning, 212

B

Beta, 133, 135, 140–142
Beta1, 133
Beta-band oscillations, 120
Beta frequency oscillations, 120
Biomarker, 294–308, 347–351, 358, 360, 361
Bipolar, 49
Bipolar depression frontolimbic dysfunction
 anterior cingulate, 31
Bipolar disorder
 ambulatory schizophrenia, 25

 gray-matter density, 36
 manic-depressive disorders, 25
 reversal learning, 36

Bipolar spectrum disorders, 49
Blood pressure (BP), 160
Boldness, 200–202, 205, 217
Borderline
 bipolar-II disorder, 26
 impulsivity, 24, 27, 32, 33
Borderline personality disorder (BPD)
 irritable temperament, 24
 manic-depression, 24
 social-class, 40
Borderline personality organization
 dissociative disorder, 33
 incest, 27
 PTSD, 27

C

Callous-unemotionality, 200
Central, 132
Childhood abuse
 temporo-limbic dysfunction, 33
Cleckley, 198, 204
Clinical utility, 50
Cognitive remediation, 302
Coherence, 315, 317, 319, 321–325, 327
Coldheartedness scale, 217
Computerized tomography (CT), 209
Conduct disorder, 200
Connectivity measures, 321
Consciousness, 3, 5–8
Correlation, 317, 322, 323, 325, 326, 317, 320, 326
Corticotropin releasing factor (CRF) neurons, 283
Cortisol, 285, 132, 133

D

Delta, 134, 135, 148, 149
 Depression, 49, 334, 346, 347, 352, 355,
 357–360, 362
 Detection, 49
 Diagnosis, 49
 Diagnostic validity, 49
 Disinhibition, 200–202, 205, 208, 217
 Disorder of hyperarousal, 277
 Dissociation, 3, 9, 10, 12
 Dissociative disorder
 dissociative amnesia, 33
 DSM-5, 198, 200
 DSM-IV, 198

E

EEG-resting state, 121
 EEG spectral frequency analyses, 281
 Electrocortical measures (EEG/ERP), 217, 218
 Electrodermal Level/Response
 Challenge, 167
 Electrodermal response, 171, 173
 Electroencephalogram (EEG), 28, 93, 175,
 258, 263, 265, 266, 268, 269, 371–374,
 376–382
 Electrophysiology, 277
 Embodied framework, 93
 EMG
 facial, 167, 163, 166, 167, 171, 173
 Emotion, 51, 200, 204, 212, 213, 218
 Emotional lability, 51
 Emotion processing, 51, 235, 236
 Error-related negativity (ERN), 207, 208, 211
 Estradiol, 230
 Event-related brain potential recording, 277
 Event-related brain potentials (ERPs), 282
 Event-related potential (ERP), 93
 Evoked oscillations, 120
 Evolutionary psychiatry
 premenstrual dysphoric disorder, 28
 Externalizing proneness, 202, 207, 208, 217

F

Fast oscillations, 120
 Fear, 201, 205, 206
 Fear and anxiety constructs, 171
 Fear extinction, 171, 172
 recall, 169
 Fearless dominance, 200, 205, 206, 214, 217

Freeman, 334
 Frick, 199, 200, 202, 205, 215
 Frontal gyrus, 213, 215
 Frontal lobe volumes
 emotional dysregulation, 29
 impulsivity, 29
 Frontal, 131–136, 141, 143
 Frontolimbic dysfunction, 29
 amygdala, 30
 anterior cingulate cortex (ACC), 30
 dorsolateral prefrontal cortex, 30
 hippocampus, 30
 ventromedial prefrontal cortex, 30
 Functional magnetic resonance imaging
 (fMRI), 93, 209, 212–215, 236, 371,
 374–382

G

Galvanic skin response (GSR), 93
 Gamma, 141, 142
 Gamma-band oscillations, 120
 Genetic (factors)
 autism, 39
 single nucleotide polymorphisms (SNPs),
 39
 Granger causality, 315, 322, 325, 327

H

Hare, 198, 199, 202, 204, 215, 217
 Heart rate (HR), 203
 baseline, 160
 challenge, 160–163, 170, 171, 173, 175
 Heart rate variability (HRV), 93, 161, 163, 174,
 175
 Hippocampus, 209–212
 HPA axis monitoring, 277
 Hypothalamic-pituitary-adrenal (HPA), 283
 Hypothalamic-pituitary-adrenal (HPA) axis
 corpus callosum, 34
 mu-opioid non-displaceable binding poten-
 tial (BP-ND), 34
 N accumbens, 34

I

Impulsivity, 200, 201
 Inferior frontal gyrus
 insula, 37
 temporal cortex, 37

- Inhibitory dyscontrol
 dysconnectivity, 37
 medial prefrontal cortex, 37
- Insula, 210, 213, 215, 216
- L**
- Lilienfeld, 199
- Lithium, 50
 clozapine, 38
 refractory BD, 38
- LORETA, 135
- Lykken, 198, 205
- M**
- Magnetoencephalography (MEG), 131, 134, 135
- Major depressive disorder (MDD), 286
- Mania, 49
- Markers, 50
- Meanness, 200–202, 205, 217
- Melatonin, 261
- Microstructure of sleep, 280
- Mild traumatic brain Injury (mTBI), 174
- Mismatch negativity (MMN), 117, 118, 296, 299
- Mood, 49
- Mood disturbances, 51
- Mood regulation, 51
- Magnetic resonance imaging (MRI), 23, 29, 31, 36, 40, 371
- Multiple sleep latency test (MSLT), 282
- N**
- N100, 105–107, 113–115, 137, 139, 141, 146, 150
- N100/P200, 134
- N200, 105, 107, 114, 115
- N400, 105, 110, 118, 119
- Networks, 315–317, 319–322, 324, 326–328
- Neural-autonomic integration, 93
- Neural network, 49
- Neural oscillations, 119, 120
- Neuroanatomy
 amygdala, 263
 anterior cingulate cortex, 267
 corpus callosum, 262
 face fusiform area (FFA), 264, 265
 gray matter, 261, 262
 mirror neuron systems, 266
 prefrontal cortex, 264
 white matter (WM), 209, 210, 262, 263
- Neurocognition, 296, 307
- Neuroimaging
 functional MRI (fMRI), 258, 262–264, 269, 258
 magnetic resonance imaging (MRI), 258, 261
- Neuroimaging (brain imaging), 198, 209, 217, 218
- Neuroimaging studies, 277
- Neuroimaging techniques, 258
- Neuronal oscillations, 315, 317, 328
- Neurophysiological alterations
 fronto-limbic malfunction, 39
- Non-linear analysis, 135
- Nucleus accumbens, 214
- O**
- Occipital, 132
- Oscillations, 119, 120
- Oxytocin, 261
- P**
- P50, 105, 106, 137–139, 141, 146
- P300, 115–117, 207, 208, 216
- P3b, 116
- Parahippocampal, 135
- Parasympathetic nervous system (PNS), 50
- Patrick, 199–201, 205, 207, 208, 216, 217
- Periaqueductal gray
 aggressive, 31
 amygdala hyperactivity, 31
 electroencephalogram (EEG), 31
 impulsive, 31
 PANIC/GRIEF system, 31
- Peripheral physiology, 49
- Personalized medicine, 49
- PET studies, 284
- Phase synchrony, 315, 317, 319, 322–325
- Phenotypes, 348, 349
- Physiological correlates, 48
- Plasma ACTH, 285
- Polysomnography (PSG), 279
- Positron emission tomography (PET), 209, 211
- Post-traumatic stress disorder
 amygdala size, 34
 depersonalization, 34
 hippocampal volumes, 34
- Prefrontal cortex (PFC), 51, 209–211, 213, 214

Premenstrual dysphoric disorder (PMDD), 230
 Prepulse inhibition, 234, 296, 299, 303
 Proactive, 205
 Proactive (instrumental premeditated) aggression, 199, 203, 211, 218
 Progesterone, 230
 P50 suppression, 378–381
 Psychopathic personality inventory (PPIInv), 199
 Psychopathy, 198–202, 204–208, 210, 212, 215, 217
 Psychopathy checklist-revised, 199
 Psychophysiology, 218

Q

Quantitative EEG (QEEG), 347, 358

R

Raine, 203, 206, 207, 209, 211, 216, 218
 Reactive (angry impulsive) aggression, 199, 203, 208
 Research domain criteria (RDoC), 49
 Respiratory sinus arrhythmia, 161
 Resting state, 112
 Resting-state EEG, 121
 Risk, 170

S

Safety signal learning, 168, 171, 172
 Schedule for the deficit syndrome (SDS), 130
 Schizophrenia, 294–296, 298–302, 305, 334, 373, 381
 Selective serotonin reuptake Inhibitors (SSRI), 260, 269
 Single-photon emission computerized tomography (SPECT), 29, 209, 211, 212
 Skin conductance (electrodermal response), 203, 205, 216
 Socioeconomic burden, 49
 Spectral, 132–134, 149
 Startle, 171, 173
 Startle reflex, 205, 217

Startle responding, 172
 Startle response
 baseline, 163
 challenge, 164
 habituation, 164
 prepulse inhibition (PPI), 165, 163
 Stimulants, 260
 Stress, 8, 12–14, 199, 203, 205
 Structural imaging, 209
 Subdimensions (factors, facets), 199, 200, 202
 Substance dependence, 201
 Subtype, 215, 218
 Suicide, 49
 Sympathetic nervous system (SNS), 50, 277, 283

T

Temporal, 134
 Temporal lobes, 211, 131, 133, 141
 Thalamic, 150, 151, 131–133
 Theta, 134
 Threat, 203, 204, 206
 Transcranial magnetic stimulation (TMS), 136
 Treatment, 50
 Treatment efficacy, 50
 Treatment response, 172
 Treatment selection, 49
 Triarchic model, 200–202
 Triarchic psychopathy measure (TriPM), 201

V

Vagal control, 203
 Ventrolateral PFC (VLPFC), 51
 Violence
 antisocial personality disorder, 32
 impulsive aggression, 32
 serotonin, 32, 198, 201, 202, 205, 212

W

Wearable physiological monitoring technology, 174